p38α Autophosphorylation Inhibitors

Research & examination
 Publication number:
 Priority date:
LUCIA DIAZ BUENO,  Lorena Gonzalez Velasco,  Ana Ignea Fernandez,  Modesto Orozco Lopez,  Ángel Rodriguez Nebreda,  Daniel Soler Viladrich,  Robert Soliva Soliva
Barcelona Supercomputing Center, Fundació Institut de Recerca Biomedica (IRB), Institucio Catalana de Recerca i Estudis Avançats (ICREA), Nostrum BioDiscovery S.L, Universitat de Barcelona


The present invention concerns inhibitors of p38α autophosphorylation, pharmaceutical compositions comprising them, and their use in the treatment of a number of diseases, such as myocardial ischemia reperfusion injury. The inhibitors satisfy the following general formula: wherein R, R1, R2, R4, and R5 may have different meanings.